A Novo Nordisk-led study comparing CagriSema, its GLP-1 drug candidate for obesity, found that Eli Lilly’s Zepbound resulted in greater weight loss.

諾和諾德領導的一項研究比較了其用於治療肥胖的GLP-1候選藥物CagriSema，發現禮來公司的Zepbound帶來了更大的減重效果。

The open-label, head-to-head trial analyzed the average weight loss among adults who received weekly injections of either CagriSema or Zepbound. After 84 weeks, the CagriSema group achieved a 20.2% reduction in weight, compared to the 23.6% weight loss with Zepbound.

開放標籤、頭對頭試驗分析了每周接受CagriSema或Zepbound注射的成年人的平均減重情況。84周後，CagriSema組體重減輕了20.2%，而Zepbound組體重減輕了23.6%。

Novo Nordisk

諾和諾德

announced

宣佈

the phase 3 trial results Feb. 23. The trial included 809 adults with obesity and at least one comorbidity, according to the Denmark-based drugmaker.

2月23日公布了第三階段試驗結果。據這家總部位於丹麥的製藥公司稱，試驗包括809名患有肥胖症且至少有一種合併症的成年人。

This trial is part of a multi-part clinical study on CagriSema including about 4,600 adults with obesity or overweight.

這項試驗是一項關於CagriSema的多部分臨床研究的一部分，包括大約4600名肥胖或超重的成年人。

In December, Novo Nordisk submitted CagriSema to the FDA for approval, and the drugmaker said a decision is expected by late 2026.

去年 12 月，諾和諾德向 FDA 提交了 CagriSema 的審批申請，該製藥商表示預計將在 2026 年底做出決定。

Recommended Whitepaper

推薦的白皮書

Eli Lilly has launched a multidose version of its blockbuster weight loss drug Zepbound that gives patients a month’s worth…

禮來公司推出了一款多劑量版本的暢銷減肥藥 Zepbound，可以為患者提供一個月的用量……

Eli Lilly has reported positive results from its phase 3b Together-PsO trial evaluating the combined use of Taltz (ixekizumab) and…

禮來公司報告了其3b期Together-PsO試驗的積極結果，該試驗評估了Taltz（ixekizumab）與…的聯合使用。

In a comparative study evaluating SGLT2 inhibitors and GLP-1 medications, the former drug class was associated with lower risk of…

在一項評估SGLT2抑制劑和GLP-1藥物的對比研究中，前者與較低的……風險相關。